Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    CAMN107AUS28
Show Display Options
Rank Status Study
1 Completed
Has Results
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: Nilotinib

Indicates status has not been verified in more than two years